Genkyotex Archives

News and Trends 2 May 2019

Drug for Autoimmune Liver Disease Yields Mixed Results in Hard-to-Treat Patients

Developed by the French biotech Genkyotex, a first-in-class treatment for the liver disease primary biliary cholangitis failed to reduce a key disease biomarker in a phase II trial, but showed potential for reducing liver scarring. Primary biliary cholangitis is an autoimmune disease that damages the liver and can lead to liver scarring (fibrosis) or the […]

May 2, 2019 - 2 minutesmins - By Jonathan Smith

autoimmune liver disease Genkyotex organ

News and Trends 7 Nov 2018

Solid Phase II Performance for French Autoimmune Liver Disease Drug

Genkyotex’s small molecule therapy had encouraging short-term effects on patients with the autoimmune liver disease primary biliary cholangitis in a Phase II trial. Over six weeks, the drug reduced the blood levels of a liver disease biomarker molecule by up to 23% in 92 participants. In patients with late-stage disease, who have few treatments available, […]

November 7, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 29 Jun 2017

This French Biotech is Starting Two New Trials to Treat Kidney and Liver Fibrosis

Genkyotex has announced a new Phase II trial in diabetic kidney disease and patient enrolment in another Phase II study for PBC. Genkyotex is not giving up after its lead candidate, GKT831, failed to meet the primary endpoint in a Phase II trial in patients with type 2 diabetes and kidney disease. The French biotech has […]

June 29, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

geneva biotech serono university of geneva

Best in Biotech 30 May 2017

In Geneva, the Capital of Peace, 10 Biotechs Are Putting up a Fight

Geneva is the largest city in French-speaking Switzerland, a financial powerhouse, home to the United Nations and known as the “Peace Capital.” Can the city’s biotech industry justify its high profile? Geneva rose to recognition as a biotech hub in 2006, when Serono sealed its acquisition by Merck in the city’s biggest-ever licensing plan. However, a late-stage […]

May 30, 2017 - 7 minutesmins - By Denise Neves Gameiro

News and Trends 3 May 2017

French Biotech gets a Second Opportunity to Fight Liver Fibrosis

Genkyotex, a French biotech with an eye on NASH, has received FDA approval to initiate a Phase II trial in primary biliary cholangitis. Genkyotex’s lead candidate, GKT831, failed to prove its efficacy in a Phase II trial for diabetic nephropathy a couple of years ago. Now, the company is taking a second shot by targeting liver […]

May 3, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 Dec 2015

Infographic: The Anatomy of European Biotech

Which part of our body do European biotechs prefer to target? And how diversified are the biotech companies in Europe nowadays? Let’s take the human body to know who works on what. From the brain to the kidney, from Genfit to Cellectis…. Here is an infographic-based overview of some of the target areas that European […]

December 10, 2015 - 1 minutemin - By Nicolas Sainte-Foie

News and Trends 10 Sep 2015

Genkyotex’ NOX inhibitor candidate Fails to follow through on Phase II

The French biotech Genkyotex has announced Phase II results for GKT137831 in diabetic kidney disease. The NOX1-4 inhibitor failed to reduce albuminuria. Genkyotex focuses on developing inhibitors of nicotinamide adenine dinucleotide phosphate-oxidase (NADPH) enzymes which are expressed by the NOX-gene family (NOX 1-5). NOX enzymes generate reactive oxidative species (ROS) which if overproduced, can cause […]

September 10, 2015 - 2 minutesmins - By Dani Bancroft

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us